Menu

Featured News

Some of the leading stories and synthetic biology information from SynbiCITE

Applications Open for Lean Launchpad for Synthetic Biology 2016

SynbiCITE is now accepting applications for the next Lean Launchpad for Synthetic Biology, which will be run from September to November 2016.

Read article

CRISPR-Cas9 genome editing partners with CAR-T cell therapy

The CRISPR-Cas9 system has rapidly become an indispensable tool in research labs around the world. Now it is finding an application as a therapeutic.

Read article

Innovation, education & collaboration

Recent developments, such as the emergence of CRISPR – a new gene editing tool with unprecedented precision, efficiency and flexibility – are creating exciting opportunities for synthetic biology in industries ranging from life sciences to specialty chemicals to bioenergy.

The vision for SynbiCITE is to create a globally renowned national resource of interacting partners from academia, industry and business, which accelerates the commercialisation of world-class science and the emerging technologies encompassed by synthetic biology and engineering biology into new products, tools and processes.

Discover more

Resources

SynbiCITE has a number of resources available to all our partners to use for the translation of their research into new products, tools and processes.

View our resources

We partner with some of the world’s most forward-thinking organisations

We support our partners through events and training programmes including problems-solutions brokerage meetings. We provide funding of development projects including seed funding of Proof of Concept projects and follow-on funding of longer, larger projects for the development of prototypes and taking these on to pilot production scale manufacturing.

View our network

Synthetic Biology community

Take a look at the active and interactive synthetic biology community. Join the conversation and get involved.
Cambridge Consultants spin-out Evonetix poised to transform synthetic biology industry

Cambridge Consultants announced the launch of a new DNA synthesis spin-out company, Evonetix. The joint venture, supported by technology entrepreneur ...

Read article
Stephen Chambers

@spchambers007

  • 2
  • 3
Stephen Chambers

@spchambers007

  • 3
  • 3
Stephen Chambers

@spchambers007

  • 0
  • 0
Stephen Chambers

@spchambers007

  • 0
  • 1
Stephen Chambers

@spchambers007

  • 0
  • 2
SynbiCITE

@SynbiCITE

  • 2
  • 1
Stephen Chambers

@spchambers007

  • 0
  • 0
CRISPR-Cas9 genome editing partners with CAR-T cell therapy

The CRISPR-Cas9 system has rapidly become an indispensable tool in research labs around the world. Now it is finding an application as a therapeutic.

Read blog article
Stephen Chambers

@spchambers007

  • 0
  • 0